Hematology

Articles

• 2019. Hoxer CS et al. – Utility valuation of health states for haemophilia and related complications in Europe and in the United States
• 2017. Carcao et al. – Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX
• 2017. Leleu X et al. – Prospective longitudinal study on quality of life in relapse/refractory multiple myeloma patients receiving second- or third line lenalidomide or bortezomib treatment
• 2016. Robinson D et al. – The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: Findings from six randomized controlled trials
• 2016. Chowdary P et al. – Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product
• 2016. Landfeldt E et al. – Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis
• 2015. Seremetis S et al. – Turoctocog alfa in the treatment of individuals with hemophilia A: Review of quality of life data collected in Phase III trials
• 2015. Acquadro C et al. – Patient-reported outcomes in drug development for hematology
• 2015. Tallman M et al. – Cost-effectiveness analysis of treating acute promyelocytic leukemia patients with arsenic trioxide and retinoic acid in the United States.
• 2015. Baz R et al. – Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
• 2015. Kruse et al. – Budgetary impact of treating acute promyelocytic leukemia patients with first line arsenic trioxide and retinoic acid from an Italian payer perspective
• 2015. Ozelo M et al. – Impact of severe haemophilia A on patients’ health status: Results from the guardian™ 1 clinical trial of turoctocog alfa (NovoEight®)
• 2014. Huisman EL et al. – Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States
• 2014. Huisman EL et al. – Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada
• 2014. Santagostino et al. – Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
• 2013. von Mackensen S et al. – Cross-cultural adaptation and linguistic validation of age-group-specific haemophilia patient-reported outcome (PRO) instruments for patients and parents
• 2013. Gaultney JG et al. – Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
• 2012. Delforge M et al. – Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: Results from the VISTA trial
• 2011. Naik S et al. – Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy
• 2011. Weatherall J et al. – Future characteristics of bypassing agents to improve care of hemophilia inhibitor patients: An economic and health-related quality of life perspective
• 2011. Naik S et al. – Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden
• 2011. Gaultney JG et al. – Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
• 2010. Van Eerd MC et al. – Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK
• 2010. Jansen JP et al. – Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands
• 2010. Zlateva G et al. – Burden of anemia in patients with osteoarthritis and rheumatoid arthritis in French secondary care
• 2010. Rofail D et al. – An instrument assessing satisfaction with iron chelation therapy: Psychometric testing from an open-label clinical trial
• 2009. Rofail D et al. – Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument
• 2008. Stam WB et al. – Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands
• 2008. Payne KA et al. – Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload

Posters & Presentations

• 2018. EAHAD Congress – Quality of life and satisfaction of children and adults with severe hemophilia A treated with turoctocog alfa pegol
• 2017- ASH Annual Meeting – Health related quality of life and satisfaction of children with severe hemophilia A treated with Turoctocog Alfa pegol (N8-GP)
• 2017. ISPOR European Congress – Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe
• 2017. ISPOR European Congress – Development and utility valuation of health states for haemophilia and related complications in Europe and in the USA
• 2016. ISPOR European Congress – Understanding the Utility Value of Patients with Heavily Pre-Treated Multiple Myeloma
• 2016. ISOQOL Annual Conference – Patient-Reported Outcomes (PROs) Used to Support Claims in Myeloproliferative Neoplasms (MPNs): A Review of the Labels of Products Approved by the EMA
• 2016. WFH World Congress – Improvement in Health Status and Quality of Life in Patients with Haemophilia B Treated with Nonacog Beta Pegol, an Extended Half-Life Glycopegylated Recombinant FIX Product
• 2016. WFH World Congress – Health-Related Quality of Life in Young Children with Haemophilia B treated with the novel long-acting nonacog beta pegol recombinant Factor IX
• 2016. ASCO Annual Meeting – Cost per Median Overall Month of Survival in Multiple Myeloma Patients with ≥3 Lines of Therapy or Were Double Refractory
• 2015. ISPOR European Congress – The Impact of Orthopaedic Surgery on the Quality of Life of Haemophilia Patients With or Without Inhibitors: A Systematic Review of the Literature
• 2015. ISOQOL Annual Conference – Challenges in Translating the Adult Version of the Transfusion-Dependent QoL (TranQoL) Questionnaire into Arabic, French, Greek, Italian and Turkish
• 2015. ISPOR Annual International Meeting – Improved Health Status of Haemophilia B Patients Treated with Nonacog Beta Pegol, A New Glycopegylated Recombinant Fix Product with Prolonged Half-Life
• 2015. ISPOR Annual International Meeting – Cost-Effectiveness Analysis of Arsenic Trioxide for the Treatment of In-Patients with Acute Promyelocytic Leukemia
• 2015. EAHAD Annual Congress – Satisfaction of Young Adults with Haemophilia A Previously Treatment with Prophylaxis and Switching to Prophylactic Treatment with Recombinant Factor VIII Turoctocog Alfa
• 2015. EAHAD Annual Congress – Quality of Life and Satisfaction of Adults with Haemophilia A Switched to Prophylactic Treatment with Recombinant Factor VIII Turoctocog Alfa
• 2014. WFH Congress – Impact of Severe Haemophilia A on Patients’ Health Status: Results from the Guardian© 1 Clinical Trial of Turoctocog Alfa
• 2013. ISPOR Annual International Meeting – Cross-Cultural Adaptation of the HAEMO-QOL Questionnaire into 28 Languages
• 2013. Annual Congress of the European Association for Haemophilia and Allied Disorders – Effect of turoctocog alfa on quality of life of children, adolescents and adults with haemophilia A: Results from two clinical trials.
• 2012. ISPOR European Congress – Development of a Generic Spanish Version of the Modified Myelofibrosis Symptom Assessment Form (MFSAF) Diary
• 2012. World Hemophilia Congress – Cross-Cultural Adaptation of the Canadian Hemophilia Outcomes – Kids’ Life Assessment Tool (CHO-KLAT) in 11 Languages
• 2012. World Hemophilia Congress – Cross-Cultural Adaptation of the Hemo-QOL Questionnaire into 28 Languages
• 2012. European Hematology Association Congress – Cost Effectiveness of Chemotherapy Regimens In Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review
• 2011. ISPOR Annual International Meeting – Hemophilia A: Patient Impact and Economic Burden of the Disease
• 2010. ISPOR European Congress – Utility Elicitation Study in the UK General Public for Late Stage Chronic Lymphocytic Leukaemia
• 2009. ISPOR European Congress – Linguistic Validation of Haemophilia-Specific Patient-Rated Outcomes (HAEMO-QOL, HAEM-A-QOL, HEMO-SAT) in up to 32 Languages
• 2009. ISPOR European Congress – Impact of Tumor Response on Health-Related Quality of Life (HRQL) in Newly Diagnosed Multiple Myeloma Patients Treated with Velcade/Prednisone (V-MP): Results from the Vista Trial
• 2008. ISPOR European Congress – Satisfaction with Iron Chelation Therapy is Associated with Improved Quality of Life in Patients with Iron Overload
• 2008. ISPOR European Congress – Health State Preference Study Mapping the Change over the Course of the Disease Process in Chronic Lymphocytic Leukaemia (CLL)
• 2008. ISPOR Annual International Meeting – Linguistic Validation of the HAEMO-QOL and HAEM-A-QOL for Use in International Studies
• 2006. ISPOR European Congress – Satisfaction with Iron Chelation Therapy and its Impact on Adherence in Patients with Beta Thalassemia Major: Results from the Ithaca Study
• 2006. ISPOR European Congress – Development and Scoring of the Satisfaction with Iron Chelation Therapy Instrument for Patients with Iron Overload
• 2005. ISPOR European Congress – The Potential Impact of Chelation Therapy (CT) on the Quality of Life (QOL) of Patients with Iron Overload (IO)
• 2005. ISPOR European Congress – The Development of a Treatment Satisfaction Questionnaire for Iron Overload (IO) Patients on Chelation Therapy (CT)